New Data from IMPROVE-IT Study of VYTORIN® (ezetimibe/simvastatin) and TRA 2ºP TIMI 50 Study of ZONTIVITY® (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions
Dateline City:
KENILWORTH, N.J.
Investigational data from IMPROVE-IT to be announced in Featured Clinical Research Session II
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that new data from two trials of the company’s
cardiovascular medicines will be presented at the 2015 American College
of Cardiology Annual Scientific Sessions (ACC.15), March 14-16 in San
Diego.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestor:Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
More News: Cardiology | Cardiovascular | Drugs & Pharmacology | Heart | Merck | Simvastatin | Statin Therapy | Study | Vytorin | Zetia | Zocor